BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

Valeant Pharma's (VRX) Proposed Credit Amendment Will Improve Liquidity Position - Moody's

August 10, 2016 10:58 AM EDT

Moody's Investors Service commented that a proposed amendment to Valeant Pharmaceutical International Inc.'s (NYSE: VRX) credit agreement will improve its liquidity position due to increased cushion under financial maintenance covenants. There is no impact on Valeant's ratings including the B2 Corporate Family Rating or the negative rating outlook.

... More

Valeant (VRX) PT Bumped to $22 at Piper Jaffray; Keeps Lowest Rating

August 10, 2016 7:04 AM EDT

Piper Jaffray analyst David Amsellem bumped his price target on Valeant Pharmaceuticals (NYSE: VRX) to $22.00 (from $19.00) but maintained an Underweight rating following results and reaffirmed guidance, which the analyst said may be overly optimistic.

Amsellem commented, "Valeant reported 2Q16 non-GAAP diluted EPS of $1.40 on revenue of $2.42B, lighter than Street... More

Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.

August 9, 2016 6:01 AM EDT

Valeant Pharma (NYSE: VRX) reported Q2 EPS of $1.40, $0.08 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $2.42 billion versus the consensus estimate of $2.46 billion.

Valeant Pharma reaffirmed FY2016 guidance. Adjusted EBITDA (non-GAAP) is expected to be in the range of $4.80 - $4.95 billion, in-line with consensus, although many expected the company to lower EBITDA guidance.

"We continue to make progress towards stabilizing the organization," said Joseph C. Papa, chairman and... More